Brazil · Delayed Price · Currency is BRL Qualicorp Consultoria e Corretora de Seguros Earnings Call Transcripts
Fiscal Year 2025
-
Strong cash generation and improved margins marked Q4 2025, with adjusted EBITDA margin rising to 41.9% and net debt down 12% year-over-year. Portfolio retention and product exclusivities improved, while sector consolidation and operator instability required agile portfolio management.
-
Revenue grew 4.3% quarter-on-quarter to BRL 372 million, with adjusted net income up 8.8% and strong cash generation. Churn hit a five-year Q3 low, and a record 340 new products were launched, while judicial claims and competitive SME pricing remain key risks.
-
Churn and net portfolio loss reached multi-year lows, driven by operational improvements, new product launches, and a focus on core retail healthcare. Revenue dipped due to portfolio divestment, but cash generation and cost control remain strong.
-
Deleveraging and cash generation remain priorities, with BRL 142 million in free cash flow and a 1.34x net debt/EBITDA ratio. Revenue declined due to a smaller customer base, but operational efficiency improved margins. Judicial contingencies remain high but are expected to decrease by year-end.
Fiscal Year 2024
-
2024 was a year of operational turnaround, with reduced costs, improved capital structure, and expanded product offerings. Despite lower revenue and EBITDA due to industry-wide lawsuits, the company achieved strong cash flow and reduced net debt, setting a foundation for sustainable growth in 2025.
-
Stable EBITDA and cash flow despite a 23% drop in managed lives, with the lowest churn in four years and strong cost discipline. New regional products and HMOs are gaining traction, while operational improvements and commercial realignment support future growth.
-
Q2 2024 saw a sharp drop in portfolio size but resilient revenue and improved EBITDA, driven by operational efficiency and cost discipline. The company is mitigating industry-wide cancellations, launching new products, and focusing on deleveraging before resuming higher dividends.